T细胞急性淋巴细胞白血病/淋巴瘤结局:聚焦近ETP表型与奈拉滨的差异影响
该回顾性研究纳入171例初诊T-ALL/LBL患者,分为ETP组27例、近ETP组24例和非ETP组120例。ETP-ALL/LBL的5年OS显著低于非ETP(32% vs 63%,p<.001),而近ETP与非ETP相似(56% vs 63%,p=.543)。首次缓解后异基因造血干细胞移植(allo-SCT)仅使ETP-ALL/LBL获益,奈拉滨加入hyper-CVAD仅在非ETP-ALL中显示生存优势。
要点
- ETP-ALL/LBL的5年OS为32%,显著低于非ETP的63%(p<.001)。
- 近ETP-ALL/LBL的5年OS为56%,与非ETP的63%相似(p=.543)。
- 首次缓解后allo-SCT仅使ETP-ALL/LBL获益,5年EFS 36% vs 18%(p=.030)。
核心结论
- ETP-ALL/LBL预后差,首次缓解后allo-SCT可改善其生存。
- 近ETP-ALL/LBL的结局与非ETP-ALL/LBL相似。
- 奈拉滨加入hyper-CVAD仅在非ETP-ALL中改善生存。
研究设计与样本
- 回顾性研究,纳入171例初诊T-ALL/LBL患者。
- 分为ETP组27例、近ETP组24例、非ETP组120例。
主要发现
- ETP vs 非ETP的5年OS为32% vs 63%(p<.001)。
- 近ETP vs 非ETP的5年OS为56% vs 63%(p=.543)。
- allo-SCT在ETP-ALL/LBL中5年EFS为36% vs 18%(p=.030)。
- 非ETP-ALL中hyper-CVAD联合奈拉滨 vs hyper-CVAD的5年OS为83% vs 38%(p=.003)。
- 多因素分析示年龄≥60岁(HR 3.11;p=.003)、WBC≥100×10^9/L(HR 2.60;p=.005)、ETP免疫表型(HR 2.29;p=.010)为OS的独立预后因素。
关键数值与推荐
- ETP免疫表型定义:CD1a阴性、CD8阴性、CD5阴性或弱阳性<75%、髓系/干细胞标志阳性。
- 近ETP-ALL:转录组与ETP-ALL相似,但CD5表达水平未低到满足ETP免疫表型标准。
临床怎么用
- 对ETP-ALL/LBL患者应考虑首次缓解后行allo-SCT以改善生存。
- 近ETP-ALL/LBL可按非ETP-ALL/LBL类似处理。
- 奈拉滨加入hyper-CVAD的生存获益仅在非ETP-ALL中观察到。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) is characterized by a distinct immunophenotype (CD1a-negative, CD8-negative, CD5-negative or weak-positive <75%, myeloid/stem-cell markers positive) and poor clinical outcomes. Near-ETP ALL is transcriptionally similar to ETP-ALL but CD5 expression level is not low enough to meet the criteria of ETP immunophenotype. Outcomes of near-ETP ALL are not well characterized. We reviewed 171 patients with newly-diagnosed T-ALL/LBL. Patients were categorized into three groups; ETP (N = 27), near-ETP (N = 24), and non-ETP ALL/LBL (N = 120). ETP-ALL/LBL was associated with a significantly worse survival compared with non-ETP ALL/LBL: 5-year overall survival (OS) rates 32% versus 63% (p < .001). Outcome was similar between near-ETP and non-ETP ALL/LBL: 5-year OS rates 56% versus 63% (p = .543). Landmark analysis showed that allogeneic stem cell transplant (allo-SCT) in first remission was beneficial in ETP-ALL/LBL (5-year event-free survival rates 36% versus 18%, p = .030) but not in near-ETP or non-ETP ALL/LBL. Multivariate analysis selected the following as significant independent prognostic factors for OS: age ≥ 60 years (HR 3.11; p = .003); elevated WBC ≥100 × 109 /L (HR 2.60; p = .005); and ETP immunophenotype (HR 2.29; p = .010). A survival advantage with adding nelarabine to hyper-CVAD was observed in non-ETP ALL (5-year OS rates 83% versus 38% with hyper-CVAD plus neralabine versus hyper-CVAD, p = .003). In conclusion, outcome of ETP-ALL/LBL was poor and improved with allo-SCT; outcome of near-ETP ALL/LBL was similar to non-ETP ALL/LBL; the addition of nelarabine to hyper-CVAD improved the survival in non-ETP ALL only.
引用
- Morita K, Jain N, Kantarjian H, et al. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol. 2021. PMID: 33639000. doi:10.1002/ajh.26144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。